RU94016525A - Methods for treating motor neurone diseases - Google Patents
Methods for treating motor neurone diseasesInfo
- Publication number
- RU94016525A RU94016525A RU94016525/14A RU94016525A RU94016525A RU 94016525 A RU94016525 A RU 94016525A RU 94016525/14 A RU94016525/14 A RU 94016525/14A RU 94016525 A RU94016525 A RU 94016525A RU 94016525 A RU94016525 A RU 94016525A
- Authority
- RU
- Russia
- Prior art keywords
- bdnf
- motor
- differentiation
- methods
- growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physical Water Treatments (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Water Treatment By Sorption (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
FIELD: medicine. SUBSTANCE: method involves administering when needed to a patient effective quantity of neurotropic factor being a representative of BDNF/NT-3/NGF molecule family supporting survival, growth and/or differentiation of motor neurones. The method utilizes the fact that BDNF and NT-3 are capable, when acting alone, stimulate choline acetyltransferase activity in cultures of motor neurones. BDNF or NT-3 combination with a second compound like CNTF is applied in treating motor neurones disorders. EFFECT: enhanced effectiveness stimulating survival, growth and/or differentiation of motor neurones; enhanced effectiveness in building animal models of motor neurone disorders.
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72770491A | 1991-07-10 | 1991-07-10 | |
US727704 | 1991-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU94016525A true RU94016525A (en) | 1996-06-10 |
Family
ID=24923677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94016525/14A RU94016525A (en) | 1991-07-10 | 1992-05-19 | Methods for treating motor neurone diseases |
Country Status (20)
Country | Link |
---|---|
EP (2) | EP0593516B1 (en) |
JP (1) | JPH06509094A (en) |
CN (1) | CN1065768C (en) |
AT (1) | ATE202939T1 (en) |
AU (2) | AU675409B2 (en) |
CA (1) | CA2113083A1 (en) |
DE (1) | DE69231930T2 (en) |
DK (1) | DK0593516T3 (en) |
ES (1) | ES2157903T3 (en) |
FI (1) | FI940098A (en) |
GR (1) | GR3036776T3 (en) |
HU (1) | HUT70275A (en) |
IE (1) | IE921602A1 (en) |
IL (1) | IL101928A0 (en) |
NO (1) | NO940084L (en) |
PT (1) | PT100501A (en) |
RU (1) | RU94016525A (en) |
SK (1) | SK2694A3 (en) |
WO (1) | WO1993001300A1 (en) |
ZA (1) | ZA923639B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2434636C2 (en) * | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Transplantation of nerve cells for treatment of neurodegenerative states |
RU2473564C2 (en) * | 2007-08-10 | 2013-01-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies with high affinity to human nerve growth factor |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993025684A1 (en) * | 1992-06-12 | 1993-12-23 | Regeneron Pharmaceuticals, Inc. | Therapeutic and diagnostic methods based on neurotrophin-4 expression |
FR2717496B1 (en) * | 1994-03-18 | 1996-04-12 | Rhone Poulenc Rorer Sa | Recombinant viruses, preparation and use in gene therapy. |
CN1112215C (en) * | 1999-12-28 | 2003-06-25 | 潘晓东 | Use of nerve growth factor in curing organic solvent toxic peripheral neuropathy |
AU2001259453B2 (en) | 2000-05-05 | 2006-08-31 | Beth Israel Deaconess Medical Center | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis |
WO2008156418A1 (en) * | 2007-06-19 | 2008-12-24 | Astrazeneca Ab | A method for screening or diagnosis of postpolio syndrome and fibromyalgia |
WO2014111525A2 (en) | 2013-01-18 | 2014-07-24 | Anaxomics Biotech, Sl | New combination therapies for treating nervous system diseases |
WO2016210325A1 (en) | 2015-06-26 | 2016-12-29 | C.R. Bard, Inc. | Connector interface for ecg-based catheter positioning system |
WO2023164311A2 (en) * | 2022-02-28 | 2023-08-31 | Bioincept, Llc | Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923696A (en) * | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
GR1000980B (en) * | 1989-08-30 | 1993-03-31 | Max Planck Gesellschaft | Neurotrophin -3,a novel neurotrophic factor related to nerve growth factor and brain derived neurotrophic factor |
US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
-
1992
- 1992-05-19 AU AU20095/92A patent/AU675409B2/en not_active Ceased
- 1992-05-19 EP EP92912453A patent/EP0593516B1/en not_active Expired - Lifetime
- 1992-05-19 JP JP5502202A patent/JPH06509094A/en active Pending
- 1992-05-19 CN CN92105070A patent/CN1065768C/en not_active Expired - Fee Related
- 1992-05-19 RU RU94016525/14A patent/RU94016525A/en unknown
- 1992-05-19 PT PT100501A patent/PT100501A/en not_active Application Discontinuation
- 1992-05-19 ES ES92912453T patent/ES2157903T3/en not_active Expired - Lifetime
- 1992-05-19 DK DK92912453T patent/DK0593516T3/en active
- 1992-05-19 IL IL101928A patent/IL101928A0/en unknown
- 1992-05-19 DE DE69231930T patent/DE69231930T2/en not_active Expired - Lifetime
- 1992-05-19 HU HU9400063A patent/HUT70275A/en unknown
- 1992-05-19 SK SK26-94A patent/SK2694A3/en unknown
- 1992-05-19 AT AT92912453T patent/ATE202939T1/en not_active IP Right Cessation
- 1992-05-19 EP EP96111711A patent/EP0755682A1/en not_active Withdrawn
- 1992-05-19 WO PCT/US1992/004228 patent/WO1993001300A1/en active IP Right Grant
- 1992-05-19 CA CA2113083A patent/CA2113083A1/en not_active Abandoned
- 1992-05-19 ZA ZA923639A patent/ZA923639B/en unknown
- 1992-07-01 IE IE160292A patent/IE921602A1/en not_active Application Discontinuation
-
1994
- 1994-01-10 NO NO940084A patent/NO940084L/en unknown
- 1994-01-10 FI FI940098A patent/FI940098A/en not_active Application Discontinuation
-
1996
- 1996-11-08 AU AU70676/96A patent/AU7067696A/en not_active Abandoned
-
2001
- 2001-10-03 GR GR20010401637T patent/GR3036776T3/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2434636C2 (en) * | 2004-11-17 | 2011-11-27 | Ньюралстем, Инк. | Transplantation of nerve cells for treatment of neurodegenerative states |
RU2473564C2 (en) * | 2007-08-10 | 2013-01-27 | Ридженерон Фармасьютикалз, Инк. | Human antibodies with high affinity to human nerve growth factor |
Also Published As
Publication number | Publication date |
---|---|
EP0593516B1 (en) | 2001-07-11 |
WO1993001300A1 (en) | 1993-01-21 |
DK0593516T3 (en) | 2001-09-17 |
EP0593516A1 (en) | 1994-04-27 |
NO940084L (en) | 1994-03-08 |
AU2009592A (en) | 1993-02-11 |
SK2694A3 (en) | 1995-02-08 |
JPH06509094A (en) | 1994-10-13 |
FI940098A0 (en) | 1994-01-10 |
DE69231930D1 (en) | 2001-08-16 |
PT100501A (en) | 1993-09-30 |
ATE202939T1 (en) | 2001-07-15 |
AU7067696A (en) | 1997-01-16 |
DE69231930T2 (en) | 2002-04-11 |
IL101928A0 (en) | 1992-12-30 |
AU675409B2 (en) | 1997-02-06 |
ES2157903T3 (en) | 2001-09-01 |
HUT70275A (en) | 1995-09-28 |
IE921602A1 (en) | 1993-01-13 |
CA2113083A1 (en) | 1993-01-21 |
HU9400063D0 (en) | 1994-06-28 |
CN1065768C (en) | 2001-05-16 |
EP0755682A1 (en) | 1997-01-29 |
EP0593516A4 (en) | 1995-01-18 |
ZA923639B (en) | 1993-02-24 |
GR3036776T3 (en) | 2002-01-31 |
FI940098A (en) | 1994-03-10 |
CN1071585A (en) | 1993-05-05 |
NO940084D0 (en) | 1994-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0203580B1 (en) | Gamma-ifn as an agent for the inhibition (hindering) of the decay process of bones | |
DE69031279D1 (en) | NEUROLOGICAL ACTIVE SUBSTANCES FOR NASAL ADMINISTRATION TO THE BRAIN | |
EA199800393A1 (en) | COMPOSITIONS AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OF DAMAGE OF BONES | |
DE68908971D1 (en) | Use of physiologically active substances for the manufacture of medicines for brain and nerve diseases. | |
ES2131525T3 (en) | THERAPEUTIC USES OF MELANINE. | |
RU94016525A (en) | Methods for treating motor neurone diseases | |
DE69637104T2 (en) | REMEDIES FOR ARTHROSIS DEFORMANS AND INFLAMMATORY JOINT DISEASES | |
EP0346501B1 (en) | Pharmaceutical preparation for treating immunodeficiency conditions | |
US6174541B1 (en) | Skin aging and wound treatment using cell migration agents | |
DE69019122T2 (en) | Stabilization and maintenance of the biological activity of the nerve growth factor using natural gangliosides or their derivatives. | |
DE59002748D1 (en) | Process for the preparation of agents for the therapy of skin diseases. | |
DE3421789C2 (en) | ||
Hanson et al. | Role of climbing fibers in determining the spatial patterns of activation in the cerebellar cortex to peripheral stimulation: an optical imaging study | |
Sandyk et al. | Age-related disruption of circadian rhythms: possible relationship to memory impairment and implications for therapy with magnetic fields | |
Johnson | Lithium effects upon components of activity in rats | |
Wright et al. | Influence of Melatonin on the Rate of Rana pipiens Tadpole Metamorphosis In Vivo and Regression of Thyroxine‐Treated Tail Tips In Vitro: (tadpole/metamorphosis/thyroxine/melatonin/tissue culture) | |
RU2090194C1 (en) | Method for producing preparation for treating coordination disturbances in cerebellum and brain stem region | |
Razumovskaya et al. | Modulation of nicotinic receptors in neurons in the common snail by Noopept and Piracetam | |
DE4436127A1 (en) | Use of benzoic or pyridine:carboxylic acid or amide cpds. | |
De Sarro et al. | Comparative epileptogenic properties of two monobactam derivatives in C57, Swiss and DBA/2 mice | |
SU1522278A1 (en) | Method of modeling increased dopjaminergic activity of subcortical formations of brain | |
RU2323723C1 (en) | Method of tretment of inflammatory deseases of salivary glands | |
EP0183253A2 (en) | Medicament comprising an organ extract from the Peyers patches for the treatment of diabetes Mellitus and Pancreatitis | |
RU94006635A (en) | Method for correcting functional state | |
Kondratenko et al. | Comenic acid prevents post-stress enhancement of long-term potentiation in rat hippocampus |